Trial · NCT04379713
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Local Reactions Within 7 Days After Dose 1 | Within 7 Days after Dose 1 | Safety population included all participants who received at least 1 dose of the investigational product with safety follow up after any dose. Participant who received incorrect vaccination was excluded from analysis. Here, Number of Participants Analyzed signifies number of participants with any e-diary data reported after Dose 1. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Local Reactions Within 7 Days After Dose 2 | Within 7 Days after Dose 2 | Safety population included all participants who received at least 1 dose of the investigational product with safety follow up after any dose. Participant who received incorrect vaccination was excluded from analysis. Here, Number of Participants Analyzed signifies number of participants with any e-diary data reported after Dose 2. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Local Reactions Within 7 Days After Dose 3 | Within 7 Days after Dose 3 | Safety population included all participants who received at least 1 dose of the investigational product with safety follow up after any dose. Participant who received incorrect vaccination was excluded from analysis. Here, Number of Participants Analyzed signifies number of participants with any e-diary data reported after Dose 3. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Local Reactions Within 7 Days After Dose 4 | Within 7 Days after Dose 4 | Safety population included all participants who received at least 1 dose of the investigational product with safety follow up after any dose. Participant who received incorrect vaccination was excluded from analysis. Here, Number of Participants Analyzed signifies number of participants with any e-diary data reported after Dose 4. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Systemic Events Within 7 Days After Dose 1 | Within 7 Days after Dose 1 | Safety population included all participants who received at least 1 dose of the investigational product with safety follow up after any dose. Participant who received incorrect vaccination was excluded from analysis. Here, Number of Participants Analyzed signifies number of participants with any e-diary data reported after Dose 1. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Systemic Events Within 7 Days After Dose 2 | Within 7 Days after Dose 2 | Safety population included all participants who received at least 1 dose of the investigational product with safety follow up after any dose. Participant who received incorrect vaccination was excluded from analysis. Here, Number of Participants Analyzed signifies number of participants with any e-diary data reported after Dose 2. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Systemic Events Within 7 Days After Dose 3 | Within 7 Days after Dose 3 | Safety population included all participants who received at least 1 dose of the investigational product with safety follow up after any dose. Participant who received incorrect vaccination was excluded from analysis. Here, Number of Participants Analyzed signifies number of participants with any e-diary data reported after Dose 3. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Systemic Events Within 7 Days After Dose 4 | Within 7 Days after Dose 4 | Safety population included all participants who received at least 1 dose of the investigational product with safety follow up after any dose. Participant who received incorrect vaccination was excluded from analysis. Here, Number of Participants Analyzed signifies number of participants with any e-diary data reported after Dose 4. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3 | From Dose 1 to 1 Month after Dose 3 | Safety population included all participants who received at least 1 dose of the investigational product with safety follow up after any dose. Participant who received incorrect vaccination was excluded from analysis. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 4 | From Dose 4 to 1 Month after Dose 4 | Safety population included all participants who received at least 1 dose of the investigational product with safety follow up after any dose. Participant who received incorrect vaccination was excluded from analysis. Here, Number of Participants Analyzed signifies number of participants who received Dose 4. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 4 | From Dose 1 to 6 Months after Dose 4 | Safety population included all participants who received at least 1 dose of the investigational product with safety follow up after any dose. Participant who received incorrect vaccination was excluded from analysis. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 6 Months After Dose 4 | From Dose 1 to 6 Months after Dose 4 | Safety population included all participants who received at least 1 dose of the investigational product with safety follow up after any dose. Participant who received incorrect vaccination was excluded from analysis. | Percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04379713/outcomes